2022年考研英语命题预测模拟试题(二)(3) Part C Directions: Read the following text carefully and then translate the underlined segments into Chinese. Your translation should be written clearly on ANSWER SHEET 2. (10points) Biotech firms are no longer mere fodder for the pharmaceutical giants AMGEN, the world”s biggest biotechnology company, made its fortune from a drug that fortifies the blood of patients who are undergoing dialysis. On December 17th, the California company acquired some new blood of its own with the purchase of Immunex, a Seattle-based biotechnology company, for $16 billion. This deal, a biotech-industry record, gives Amgen a firm footing in the multibillion-dollar market in inflammation control. Immunex”s most lucrative product is Enbrel, a treatment for rheumatoid arthritis.(46) Amgen hopes to triple the drug”s sales to more than $3 billion by 2022, widening its use to other diseases, such as psoriasis, and overcoming manufacturing constraints that have kept the drug in short supply. With this takeover, Immunex passes from one parent to another. American Home Products (AHP) holds 41% of the shares, and has given the firm sales and marketing support. (47)But AHP has been selling down its stake since last year, in part to finance a $3.8 billion settlement of claims against its diet drugs. (48)Although Amgen calls itself a biotech company, its market capitalisation of around $62 billion makes it larger than Pharmacia and several other well-known mainstream drug companies, traditionally considered the big brothers of biotech. But Amgen likes to think of itself as less bureaucratic and more entrepreneurial than its pharmaceutical brethren, and it is free of such big-pharma woes as imminent patent expiry. (49)However, as Joseph Dougherty, a biotech analyst at Lehman Brothers, points out, Amgen will find it hard to retain the freedom of its nimble youth as it strives to expand its sales by more than 30% a year.